Articles On Factor Therapeutics (ASX:FTT)
| Title | Source | Codes | Date |
|---|---|---|---|
|
Check up: What’s happening with ASX small cap health stocks
Here’s our fortnightly wrap of all the news driving ASX small cap health stocks. We last checked in with ASX small cap health stocks just hours after Opthea’s (ASX:OPT) anti macular degeneration drug passed a large clinical test with flying... |
Stockhead | FTT | 4 years ago |
|
Dr Boreham’s Crucible: Opthea needs some big licks of dough, but it has set itself up for success
Coming after trial flops from Factor Therapeutics (ASX:FTT), Innate Immunotherapeutics (now Amplia Therapeutics, ASX:ATX) and Bionomics (ASX:BNO), investors were awaiting the phase IIb results from the eye diseases house with more than a de... |
Stockhead | FTT | 4 years ago |
|
Updates On Change In Directors’ Interest On Stocks – MFG, RFF, 1AD, JHG, KMD, FUN
As per the announcements on ASX, all the six stocks have released updates on changes in directors’ interest, appointment/resignation/retirement from the Board and changes in the shareholding. Let us now have a detailed look at the updates... |
Kalkine Media | FTT | 4 years ago |
|
Warning: These are the 10 worst small-cap shares of FY 2019
The small-cap or ‘casino’ end of the share market is a veritable minefield suitable for highly-experienced investors only. However, this does not stop beginner investors or speculators regularly trading shares in the hope of a quick profit... |
Motley Fool | FTT | 4 years ago |
|
Trading Places: After three years of suspension, this tin company raised $20 million
In this week’s recap of substantial holders, a Dubai executive bought into Prospect Resources (ASX: PSC), Salt Funds Management sold $8.3 million of Monash IVF (ASX: MVF) and a tin company raised $20 million to save itself from the ‘three-y... |
Stockhead | FTT | 4 years ago |